Literature DB >> 21221414

A Unified Approach of Meta-Analysis: Application to an Antecedent Biomarker Study in Alzheimer's Disease.

Chengjie Xiong1, Gerald van Belle, Kejun Zhu, J Philip Miller, John C Morris.   

Abstract

This article provides a unified methodology of meta-analysis that synthesizes medical evidence by using both available individual patient data (IPD) and published summary statistics within the framework of likelihood principle. Most up-to-date scientific evidence on medicine is crucial information not only to consumers but also to decision makers, and can only be obtained when existing evidence from the literature and the most recent individual patient data are optimally synthesized. We propose a general linear mixed effects model to conduct meta-analyses when individual patient data are only available for some of the studies and summary statistics have to be used for the rest of the studies. Our approach includes both the traditional meta-analyses in which only summary statistics are available for all studies and the other extreme case in which individual patient data are available for all studies as special examples. We implement the proposed model with statistical procedures from standard computing packages. We provide measures of heterogeneity based on the proposed model. Finally, we demonstrate the proposed methodology through a real life example studying the cerebrospinal fluid biomarkers to identify individuals with high risk of developing Alzheimer's disease when they are still cognitively normal.

Entities:  

Year:  2011        PMID: 21221414      PMCID: PMC3017356          DOI: 10.1080/02664760903008987

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.404


  35 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

Authors:  M Riemenschneider; M Schmolke; N Lautenschlager; W G Guder; H Vanderstichele; E Vanmechelen; A Kurz
Journal:  Neurosci Lett       Date:  2000-04-21       Impact factor: 3.046

3.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

4.  Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.

Authors:  Jesse A Berlin; Jill Santanna; Christopher H Schmid; Lynda A Szczech; Harold I Feldman
Journal:  Stat Med       Date:  2002-02-15       Impact factor: 2.373

5.  Detecting and describing heterogeneity in meta-analysis.

Authors:  R J Hardy; S G Thompson
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

6.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

7.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

8.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group.

Authors:  L A Stewart; M J Clarke
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

9.  Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.

Authors:  Christopher H Schmid; Paul C Stark; Jesse A Berlin; Paul Landais; Joseph Lau
Journal:  J Clin Epidemiol       Date:  2004-07       Impact factor: 6.437

10.  Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.

Authors:  R H Myers; E J Schaefer; P W Wilson; R D'Agostino; J M Ordovas; A Espino; R Au; R F White; J E Knoefel; J L Cobb; K A McNulty; A Beiser; P A Wolf
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.